4D Molecular Therapeutics (FDMT) Amortizatization of Intangibles (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Amortizatization of Intangibles of $1.1 million for Q1 2026, down 10.5% year-over-year from $1.3 million in Q1 2025, and down 1.13% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Amortizatization of Intangibles for 6 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 10.5% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $4.6 million (down 40.18% YoY), while the FY2025 annual figure was $4.7 million, down 34.09% from the prior year.
- Amortizatization of Intangibles slipped to $1.1 million in Q1 2026 per FDMT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.3 million in Q2 2024 and bottomed at -$582000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $778529.4 across 5 years, with a median of $757000.0 in 2024.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles soared 1393.33% — and 2025, when it tumbled 50.06%.
- 4D Molecular Therapeutics' Amortizatization of Intangibles stood at $231000.0 in 2022, then soared by 107.36% to $479000.0 in 2023, then surged by 286.22% to $1.8 million in 2024, then sank by 38.0% to $1.1 million in 2025, then slipped by 1.13% to $1.1 million in 2026.
- Business Quant data shows FDMT's Amortizatization of Intangibles at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | 990,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 990,000.00 |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 2.34 Mn |
| Mar 31, 2024 | 757,000.00 |
| Dec 31, 2023 | 411,000.00 |
| Sep 30, 2023 | 402,000.00 |
| Jun 30, 2023 | 337,000.00 |
| Mar 31, 2023 | 395,000.00 |
| Dec 31, 2022 | 2.77 Mn |
| Sep 30, 2022 | -239,000.00 |
| Jun 30, 2022 | -469,000.00 |
| Mar 31, 2022 | -582,000.00 |
| Dec 31, 2021 | 380,000.00 |
| Sep 30, 2021 | 380,000.00 |